Cadonilimab

Cadonilimab (code name AK104, brand name Kaitanni in China) is Akeso's bispecific antibody that hits both PD-1 and CTLA-4 on the same molecule [1]. It is already approved in China for recurrent or metastatic cervical cancer (2022) and first-line gastric/gastroesophageal junction cancer in combination with XELOX chemotherapy (2024, based on the AK104-302 Phase 3 trial that showed a 4-month overall survival benefit) [7][9]. It is now in Phase 3 as consolidation therapy after chemoradiation in unresectable stage III non-small cell lung cancer (NCT06617416), going head to head with sugemalimab [5]. The commercial question is whether a single bispecific can match the efficacy of the ipilimumab plus nivolumab combination without the autoimmune toxicity that has limited combo uptake, and whether Akeso can push the drug beyond its China footprint into global markets where PD-1 monotherapy is entrenched. As of mid-2026, no US regulatory pathway has been announced and no Western partner has been signed.

Cadonilimab is not a new molecule. China's NMPA approved it in June 2022 for platinum-refractory recurrent or metastatic cervical cancer, making it the first PD-1/CTLA-4 bispecific to reach market anywhere [7]. A second NMPA approval followed in 2024 for first-line unresectable, locally advanced, recurrent or metastatic gastric or gastroesophageal junction (G/GEJ) adenocarcinoma in combination with XELOX (capecitabine plus oxaliplatin). That approval was supported by the AK104-302 Phase 3, which met its primary endpoint of overall survival at interim analysis with median OS of 14.3 months for cadonilimab plus XELOX versus 10.3 months for placebo plus XELOX in the all-comer intent-to-treat population, a statistically significant benefit that did not require PD-L1 selection [9]. Outside China the drug has no approvals and no active FDA regulatory dossier. No breakthrough therapy, fast track, orphan, or priority review designation from FDA appears on the public record. The Phase 3 in the node data (NCT06617416) compares AK104 against sugemalimab as consolidation therapy after concurrent chemoradiation in unresectable stage III NSCLC, run by Akeso in China [5]. Readout timelines for that trial are not published in the ClinicalTrials.gov record; consolidation trials of this size typically report at 24 to 36 months from full enrollment. Additional Phase 3 activity spans perioperative colorectal cancer (following the positive OPTICAL-2 Phase 2) [2] and endometrial cancer (Phase 2 interim published 2026) [3]. A Phase 2 conversion-therapy study in unresectable HCC combines cadonilimab with hepatic arterial infusion chemotherapy and lenvatinib (NCT06187961) [6]. Near-term expansion is entirely China-anchored. A Western pathway would likely require a partner, and no such deal has been announced, though Akeso received FDA clearance in late 2025 for a global Phase 3 first-line gastric cancer trial versus nivolumab, its first meaningful step toward a US regulatory path.

PD-1 and CTLA-4 are two brakes that tumors use to keep the immune system off their backs. PD-1 sits on T cells and gets pressed when the tumor waves the PD-L1 flag, telling the T cell to stand down. CTLA-4 sits on the same T cells earlier in their life cycle and dampens the initial priming that happens in lymph nodes, before the T cells ever reach the tumor. Blocking either brake alone (Keytruda, Opdivo) works, and blocking both together (Yervoy plus Opdivo) works better in melanoma and some other tumors, at the cost of steep autoimmune toxicity. Cadonilimab tries to solve the toxicity problem with geometry. Because both binding arms are on the same molecule, the drug preferentially engages T cells where PD-1 and CTLA-4 are co-expressed, which happens most inside tumors and least in peripheral tissue. In principle, this concentrates the double blockade at the tumor and spares the healthy immune system [1]. The mechanism is well validated at the target level: PD-1 blockade underpins roughly $29.5B in 2024 global revenue for Keytruda alone (per Merck's 2024 full-year results, an 18% year-over-year increase) [10], and combined PD-1/CTLA-4 blockade is standard of care in first-line melanoma and MSI-high colorectal cancer. What is not yet validated is whether the bispecific geometry actually delivers the promised toxicity advantage in a proper head-to-head against ipilimumab plus nivolumab, a question the Chinese Phase 3 datasets have suggested but not resolved.

NCT06617416 is a Phase 3 randomized trial testing cadonilimab versus sugemalimab as consolidation therapy in unresectable stage III NSCLC patients who did not progress after concurrent or sequential chemoradiation [5]. This is the PACIFIC setting, named for the landmark 2018 trial that established durvalumab (Imfinzi) as standard of care in stage III NSCLC after chemoradiation and now generates roughly $4B a year globally for AstraZeneca. Sugemalimab (a PD-L1 antibody from CStone) is the recent Chinese entrant in the same setting. Choosing sugemalimab rather than durvalumab as the comparator flags this as a China-market study. Sugemalimab is approved in China for the indication but carries no US label. Enrollment target, primary endpoint (typically progression-free survival in the consolidation setting), and stratification factors are not fully disclosed in the current registry snapshot, and the trial's enrollment status is not clearly stated in the public record. Broader cadonilimab Phase 3 activity gives more surface area to evaluate the molecule. OPTICAL-2 randomized locally advanced colorectal cancer patients to neoadjuvant mFOLFOXIRI (modified 5-FU, leucovorin, oxaliplatin, and irinotecan, a standard triplet chemotherapy backbone) with or without cadonilimab versus mFOLFOX6 (5-FU, leucovorin, and oxaliplatin, the standard doublet) and reported positive pathologic response signal in 2026 [2]. A Phase 2 in PD-L1-negative first-line NSCLC (cadonilimab plus chemo) published in Nature Communications in 2026, a notable subgroup because these patients respond poorly to monotherapy PD-1 blockade [4]. Interim Phase 2 data in first-line advanced or recurrent endometrial cancer published in Gynecologic Oncology in 2026 [3]. NCT06187961 is a single-arm Phase 2 conversion-therapy trial combining cadonilimab with lenvatinib and HAIC (hepatic arterial infusion chemotherapy, in which chemo is delivered directly into the hepatic artery to concentrate exposure in the liver) in initially unresectable HCC, with conversion to curative surgical resectability as the primary endpoint [6]. A systematic review across solid tumors in 2026 aggregated the safety and efficacy signal across programs [1].

Our model estimates a 11% chance this drug is eventually approved. It starts from the historical base rate for Phase 3 drugs in this area (about 48%), then adjusts using ten facts about the trial and sponsor. What moves the number most: it is held back by heavier-than-usual blinding, the sponsor's thin or weak approval record, weak or limited earlier-phase results, and a randomized design. The other facts land near average for this stage, so they leave the estimate roughly where the base rate put it.

Efficacy risk is the top concern. Consolidation in stage III NSCLC has been a graveyard for me-too PD-1/PD-L1 assets trying to displace durvalumab, and even a clean win over sugemalimab in China does not automatically translate to a durvalumab-competitive profile globally. Safety risk is real but not catastrophic. The bispecific geometry appears to reduce Grade 3+ immune-related adverse events versus ipilimumab plus nivolumab combos in Chinese studies [1], but rates of colitis, pneumonitis, and hepatitis remain meaningful, particularly when the drug is combined with chemo or radiation. Regulatory risk outside China is severe. China-only Phase 3 data has faced escalating FDA skepticism since the sintilimab complete response letter in 2022, and Akeso would need US or global bridging trials to secure a Western label; the FDA-cleared global gastric Phase 3 versus nivolumab is the first such trial and will take years to read out. Commercial risk cuts two ways. Inside China the drug is scaling but pricing is set by NRDL (National Reimbursement Drug List) negotiations, which typically cut list price by 50 to 80 percent for oncology drugs (as seen with sintilimab and camrelizumab), capping per-patient revenue sharply. Outside China cadonilimab faces well-entrenched competition (Keytruda, Opdivo plus Yervoy, Imfinzi) and a rising bispecific pipeline including AstraZeneca's volrustomig (also PD-1/CTLA-4) and Akeso's own ivonescimab (PD-1/VEGF), the latter arguably a more commercially interesting molecule after Summit Therapeutics licensed it for the West in a deal worth $500M upfront and up to $5B total including regulatory and commercial milestones, plus low double-digit royalties on net sales [8]. No comparable Western deal exists for cadonilimab. Execution risk is elevated by concurrent Phase 3 activity across at least three tumor types, spreading Akeso's operational bandwidth thin.

Watch, but not for this specific trial. The NSCLC consolidation Phase 3 (NCT06617416) is a China-market defensive study, useful for Akeso revenue but unlikely to move global thinking [5]. The signals worth tracking are elsewhere. First, readouts from perioperative expansion of OPTICAL-2 in colorectal cancer [2] and the Phase 2 HCC conversion-therapy study [6], both of which would extend the drug into settings where combination immunotherapy has real unmet need. Second, any announcement of a Western partnership or out-licensing deal, which would be the real inflection point for cadonilimab commercially and would echo the Summit-Akeso ivonescimab template ($500M upfront, up to $5B total) [8]. Third, direct head-to-head data against ipilimumab plus nivolumab, which is the trial that would either validate or kill the bispecific-geometry-equals-lower-toxicity thesis for the whole class. Fourth, updates on the FDA-cleared global Phase 3 first-line gastric trial versus nivolumab, the first meaningful cadonilimab dataset that will be generated outside China. Akeso is the company to track, not this specific trial. The stock trades in Hong Kong (9926.HK), and the ivonescimab program is a much larger swing factor for the company than cadonilimab is at this point. Next catalysts: ESMO Congress (Berlin, September 2026) and ESMO Asia (December 2026) for updated NSCLC, gastric, and colorectal datasets.